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Abstract
Background: Genetic variations in the calpain-10 gene (CAPN10), in particular the at-risk diplotype (112/121), were 
previously implicated with increased risk of type 2 diabetes (T2D).
Methods: We examined the association of CAPN10 UCSNP-43 (rs3792267), UCSNP-19 (rs3842570), and UCSNP-63 
(rs5030952) SNPs with T2D in 917 Tunisian T2D patients and 748 non-diabetic controls. CAPN10 genotyping was done 
by PCR-RFLP.
Results: Enrichment of UCSNP-19 2R (minor) allele and 2R/2R genotype was found in T2D patients; the allele and 
genotype distribution of UCSNP-43 and UCSNP-63 alleles and genotypes were not significantly different between 
patient groups and non-diabetic control subjects. Regression analysis demonstrated progressive increases in T2D risk 
in 3R/2R [OR (95% CI) = 1.35 (1.08 - 1.68)] and 2R/2R [OR (95% CI) = 1.61 (1.20 - 2.18)] genotypes. Of the six haplotypes 
detected, enrichment of haplotype 111 (UCSNP-43/UCSNP-19/UCSNP-63) was seen in patients (Pc = 0.034); the 
distribution of the other haplotypes was comparable between patients and control subjects; neither haplotype 211 
nor haplotype 212 was observed. Furthermore, the frequency of all CAPN10 diplotypes identified, including the "high-
risk diplotype (112/121) reported for Mexican-Americans and Northern Europeans, were comparable between patients 
and controls.
Conclusions: CAPN10 UCSNP-19 variant, and the 111 haplotype contribute to the risk of T2D in Tunisian subjects; no 
significant associations between CAPN10 diplotypes and T2D were demonstrated for Tunisians.
Background
Type 2 diabetes (T2D) is a metabolic disorder character-
ized by impaired insulin-stimulated glucose uptake in
muscle and fat, altered glucose-induced insulin secretion,
and increased hepatic glucose production. Insofar as T2D
is triggered by genetic and environmental risk factors,
several genome-wide scan studies on different ethnic
groups reported linkage at the same or different chromo-
somes with T2D [1,2]. Of the diabetes-related genes, fine
mapping and positional cloning suggested that the cal-
pain-10 (CAPN10) gene might serve as an important T2D
susceptibility gene [3,4]. Similar to other calpains,
CAPN10 consists of an isoform-specific large subunit
and a common small subunit, and was shown to function
as intracellular calcium-dependent cysteine proteases in
calcium-regulated signaling pathways [5]. CAPN10 is
expressed at the mRNA and protein levels by several tis-
sue types, with different mRNA isoforms reported, in
particular those involved in the regulation of glucose
homeostasis, such as pancreatic β islet cells, liver, skeletal
muscle, and adipocytes [6,7].
CAPN10 is located on chromosome 2q37.3, and com-
prises 15 exons spanning 31 kb, and encodes a 672
amino-acid intracellular protease. Several case control
and association studies indicated that polymorphisms in
CAPN10  are associated with the development of T2D
and insulin resistance, more so in obese patients with an
earlier age of disease onset [6,8-10]. These include the at-
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risk UCSNP-43 G/A variant located in the third intron,
UCSNP-19 2R (two 32-bp repeats)/3R (three 32-bp
repeats) present in intron 6, and UCSNP-63 C/T variant
within CAPN10 intron 13 [7,10]. This contribution of the
CAPN10 variants to T2D pathogenesis was highlighted
by the findings that select UCSNP-43/UCSNP-19/
UCSNP -63 haplotypes (112 and 121) were associated
with heightened risk of T2D in select ethnic groups, and
as at-risk dipolotypes (haplotype combinations) were
reported for many populations [10-13]. The reported
association of UCSNP-43/UCSNP-19/UCSNP -63 112/
121 diplotype with increased T2D risk in Mexicans
Americans, German and Finnish populations exemplified
this association [10,11].
A number of studies from diverse populations have
confirmed the initial findings [6,14], while some did not
[15,16]. Others showed a trend towards significance, but
were underpowered to detect a meaningful effect [17].
We previously reported on the association of select vari-
ants of the recently identified T2DM candidate genes
with T2D in Tunisia [18]. The aim of this study was to
investigate whether UCSNP-43, UCSNP-19, and UCSNP-
63 CAPN10 variants, alone or at-risk haplotype and hap-
lotype combination (diplotype] were associated with T2D
in a group of Tunisian T2D patients and non-diabetic
control subjects.
Methods
Study population
A total of 917 consecutive unrelated adult patients with
documented medical records of T2D were recruited from
outpatient endocrinology clinics in Southern, Central and
Northern Tunisia by referral from the treating physician,
after obtaining initial verbal consent to participate in the
study. In addition, 748 control subjects from the same
area as the patients, and comprising blood donors,
healthy volunteers, or hospital/university staff members
w e r e  e n r o l l e d  i n  t h i s  s t u d y .  C o n t r o l s  w e r e  f r e q u e n c y -
matched with patients according to age (P = 0.160), eth-
nic origin (all of Arab descent), and gender (P = 0.126),
and had to meet the following conditions: normoglyce-
mia (fasting glucose < 5.6 mmol/L) and no personal or
first-degree history of diabetes. Diabetes diagnosis was
based on clinical features as per World Health Organiza-
tion criteria. None of the patients had ketoacidosis, and
initial T2D treatment comprised diet and/or oral anti-
diabetic drugs; patients who required insulin had been
treated with oral drugs for at least two years (Table 1).
The patients had a mean age of 59.3 years (range 35 - 86
years), BMI of 29.0 kg/m2 (range 18.4 - 39.2 kg/m2), and
average T2D duration of 12.6 years (range 5 - 36 years),
with 330 patients (36.0%) reporting positive family his-
tory of diabetes. The control subjects had a mean age of
58.7 years (range 45 - 88 years), and mean BMI of 23.5 kg/
m2 (range 18.2-27.0 kg/m2). None of the control subjects
was taking regular medication, including slimming diet, 6
months prior to inclusion into the study.
Blood pressure (BP; right arm) was measured twice,
using mercury sphygmomanometer with participants in
the sitting position following a 5 min rest; the mean of
two readings measured 1 minute apart was adopted.
Hypertension was determined as BP readings of 145/90
mmHg or higher, and/or use of antihypertensive medica-
tions. Demographic details were obtained for all subjects,
which included age, gender, BMI, age at onset and dura-
tion of diabetes, first-degree family history of diabetes,
history of chronic diabetes complications, and treatment
of diabetes. The historical information was verified from
the clinic records where available. Written informed con-
sent was obtained from all participants, and the study was
carried out in accordance with the guidelines of the Hel-
sinki Declaration of 1975, and was approved by the Uni-
versity of Monastir Ethics Committee. Venous blood
samples were collected after an overnight fast for measur-
ing plasma glucose, HbA1c, and serum lipids.
CAPN10 Genotyping
Genomic DNA was isolated from the from the leukocyte-
rich buffy coat layer of peripheral venous blood using a
QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA).
The study groups were genotyped for the CAPN10
UCSNP-43, -19, and -63 polymorphisms as previously
described [19,20]. The insertion-deletion UCSNP-19
variant (rs3842570) was genotyped by PCR using the fol-
lowing primers, (forward) 5'-GTT TGG TTC TCT TCA
GCG TGG AG-3' and (reverse) 5'-ATG AAC CCT GGC
AG G GTC TAA G-3'. PCR fragments were separated on
a 4% Nusieve agarose gel; the two 32 bp repeats 2R allele
and the three 32-bp repeats 3R allele visualized as155 bp
and 187 bp, respectively. UCSNP-43 (rs3792267) was
genotyped using the forward primer 5'-CAC GCT TGC
TGT GAA GTA ATG C-3', and the reverse primer, 5'-
CTC TGA TTC CCA TGG TCT GTA G-3', and subse-
quent digestion with NsiI (Promega, Madison, WI); the
UCSNP-43 alleles seen as 144 bp (G allele) 121 + 23 bp
fragments (A allele). UCSNP-63 (rs5030952) was geno-
typed using the forward primer 5'-AGC ACT CCC AGC
TCC TGA TC-3' and the reverse primer 5'-AAG GGG
GGC CAG GGC CTG ACG GGG GTG GCG-3', and
digestion with HhaI (Promega); the UCSNP-63 alleles
seen as 162 bp (C allele) and 192 bp fragment (T allele).
All genotyping was carried out in the same laboratory
(University of Monastir), and was done in blinded fashion
(case/control sample status). Inter-laboratory quality
controls comprised independent genotyping of a number
of case and control samples by personnel unaware of the
phenotype of the samples. Genotyping call rate exceededEzzidi et al. BMC Medical Genetics 2010, 11:75
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99%, with no significant differences between cases and
control samples.
Statistical Analysis
Statistical analysis was performed on SPSS v.17.0 soft-
w a r e  ( S P S S  I n c. ,  C h i c a g o ,  I L ) .  D a t a  w e r e  e x p r e s s e d  a s
mean ± SD for continuous variables that were normally
distributed, or as percentages of total for categorical vari-
ables. Pearson χ2 test were used to assess inter-group sig-
nificance, and Student's t-test was used to determine
differences in means. Allele frequencies were calculated
by the gene-counting method, and differences in the
allele and genotype frequencies were tested by χ2 test.
Haplotype estimation and determination of diplotype
frequencies were done by the expectation maximization
(EM) method using HPlus 2.5 software, which is an itera-
tive method that alternates between performing an
expectation (E) step (expectation of the log likelihood
with respect to the current estimate of the distribution
for the latent variables), and a maximization (M) step,
which computes the parameters which maximize the
expected log likelihood found in the E step. Univariate
and multivariate regression analysis were determined
using HPlus 2.5 and HAPStat; results being expressed as
p  value, odds ratio (OR) and 95% confidence intervals
(CI). Statistical significance was set at P < 0.05. The link-
age disequilibrium among CAPN10 SNPs were calculated
by an expectation-maximization algorithm and haplotype
frequencies were estimated by LDA v.1.0 software [21].
Results
Study Subjects
The demographic and clinical characteristics of T2D
patients and controls (Control/Case ratio = 0.82) are
shown in Table 1. Patients and control subjects were
matched for gender, age, ethnic origin (all Arab subjects),
and geographical origin (all originating from Central
Tunisia); significant differences were noted between the
two groups with regards to BMI (P < 0.001), blood pres-
sure (P < 0.001), lipid profile (P < 0.001), urea (P < 0.001),
and fasting glucose (P < 0.001) and HbA1c levels (P <
0.001). T2D duration was 12.6 years (range: 5 - 36 years),
with an average age at T2D onset of 46.7 ± 10.9 years.
CAPN10 Allele and Genotype Frequencies
The genotype frequencies of UCSNP-43 (P = 0.291; χ2 =
1.12), UCSNP-19 (P = 0.228; χ2 = 1.45), and UCSNP-63 (P
= 0.506; χ2 = 0.44) were in Hardy-Weinberg Equilibrium.
The distribution of UCSNP-43 genotypes (G/G, P  =
0.255; G/A, P = 0.332, and A/A, P = 0.518) or minor allele
frequency (MAF) (P = 0.359), and UCSNP-63 genotypes
(C/C, P = 0.702; C/T, P = 0.895, and T/T, P = 0.530) or
MAF (P = 0.673) was similar between patients and con-
trols (Table 2). The distribution of UCSNP-19 genotypes
(3R/3R,  P  = 0.001, 2R/2R, P  = 0.020), and MAF (P  =
0.007), were significantly different between patients and
controls (Table 2). Homozygosity for the UCSNP-19 2R
was associated with increased body weight among
patients (OR = 2.17; 95% CI = 1.33 - 3.51) (data not
Table 1: Demographic and Clinical Characteristics of Study Subjects
Characteristic T2D Patients (917) Controls (748) P
Gender (M:F) 422:495 373:375 0.126
Mean Age (years) 59.3 ± 10.9 58.7 ± 8.7 0.160
Mean B.M.I. (kg/m2) 27.7 ± 4.3 23.5 ± 2.2 < 0.001
Systolic BP (mmHg) 140.7 ± 27.0 121.6 ± 14.4 < 0.001
Diastolic BP (mmHg) 81.9 ± 12.6 77.9 ± 10.5 < 0.001
Hypertension2 420 (45.8) 86 (18.0) <0.001
Fasting glucose (mmol/L) 12.8 ± 5.3 5.1 ± 0.6 < 0.001
HbA1c (%) 9.6 ± 3.9 4.5 ± 1.4 < 0.001
Age at disease onset (years) 46.7 ± 10.9 N/A N/A
T2D Duration (years) 12.6 ± 6.3 N/A N/A
Total cholesterol (mmol/L) 5.3 ± 1.4 4.7 ± 1.2 < 0.001
Triglycerides (mmol/L) 1.9 ± 1.3 1.2 ± 0.6 < 0.001
HDL (mmol/L) 1.1 ± 0.3 1.2 ± 0.4 < 0.001
LDL (mmol/L) 3.8 ± 1.4 2.8 ± 1.8 < 0.001
Urea (mmol/L) 7.9 ± 4.8 5.6 ± 2.1 < 0.001
1. Student t-test for continuous variables, chi square for categorical variables.
2. Defined as BP reading ≥ 145/90 mmHg, and/or use of anti-hypertension medication.Ezzidi et al. BMC Medical Genetics 2010, 11:75
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shown). The association of UCSNP-19 genotypes with
increased T2D risk was confirmed by regression analysis.
Taking homozygous wild-type genotype as reference (OR
= 1.00), regression analysis demonstrated progressive
increases in T2D risk in 3R/2R [P = 0.008; OR (95% CI) =
1.35 (1.08 - 1.68)] and 2R/2R [P = 0.002; OR (95% CI) =
1.61 (1.20 - 2.18)] genotypes (Table 3). The association of
homozygous UCSNP-19 2R/2R [P = 0.044; aOR (95% CI)
= 1.40 (1.01 - 1.93)], but not 3R/2R [P = 0.923; aOR (95%
CI) = 1.02 (0.66 - 1.58)] genotype with changes in BMI
remained significant after controlling for age, gender,
BMI, hypertension, and lipid profile (Table 3).
Haplotype and Diplotype Distribution
Linkage disequilibrium (LD) analysis for the CAPN10
variants, defined by the delta coefficient, showed a weak
negative LD between these SNPs. LD among the three
markers (r2) ranged from 0.001 to 0.083 in T2D subjects
and from 0.002 to 0.076 in non-diabetic controls (Table
4). Six possible CAPN10 haplotypes were inferred, and
neither haplotype 211 nor haplotype 212 was observed.
Enrichment of only haplotype 111 was seen in patient [Pc
= 0.034; OR (95% CI) = 1.22 (1.06 - 1.41)]; the distribution
of the other haplotypes was comparable between unse-
lected patients and control subjects (Table 5). Data from
Table 2: UCSNP-43, UCSNP-19 and UCSNP-63 Allele and Genotype Distribution
SNP Allele/Genotype Patients (917) Controls (748) P 1
UCSNP-43 MAF2 (A) 0.088 0.101 0.359
G/G 759 (0.828) 602 (0.805)
G/A 155 (0.178) 141 (0.189) 0.343
A/A 3 (0.003) 5 (0.007)
UCSNP-19 MAF (2R) 0.464 0.404 0.007
3R/3R 247 (0.269) 258 (0.345)
3R/2R 489 (0.533) 376 (0.503) 0.001
2R/2R 181 (0.197) 114 (0.152)
UCSNP-63 MAF (T) 0.162 0.170 0.673
C/C 638 (0.696) 513 (0.686)
C/T 261 (0.285) 216 (0.289) 0.704
T/T 18 (0.020) 19 (0.025)
1. Pearson chi square test
2. MAF = minor allele frequency.
Table 3: Regression Analysis on T2D Risk Associated with CAPN10 Polymorphisms 1
Univariate Multivariate
SNP Genotype P OR (95% CI) P aOR 2 (95% CI)
UCSNP-43 G/G 0.647 1.00 (Reference) 3 0.809 1.00 (Reference) 3
G/A 0.573 1.52 (0.35 - 6.53) 0.827 1.20 (0.24 - 6.12)
A/A 0.492 1.66 (0.39 - 7.03) 0.708 1.36 (0.27 - 6.85)
UCSNP-19 3R/3R 0.003 1.00 (Reference) 3 0.084 1.00 (Reference) 3
3R/2R 0.008 1.35 (1.08 - 1.68) 0.923 1.02 (0.66 - 1.58)
2R/2R 0.002 1.61 (1.20 - 2.18) 0.044 1.40 (1.01 - 1.93)
UCSNP-63 C/C 0.714 1.00 (Reference) 3 0.704 1.00 (Reference) 3
C/T 0.463 1.29 (0.66 - 2.52) 0.722 1.19 (0.45 - 3.17)
T/T 0.417 1.31 (0.68 - 2.54) 0.920 1.05 (0.39 - 2.85)
1. Study subjects comprised 917 cases and 748 age-, gender-, and origin-matched controls subjects.
2. aOR = adjusted OR; covariates included age, gender, BMI, hypertension, and lipid profile.
3. Reference group being minor allele non-carriers.Ezzidi et al. BMC Medical Genetics 2010, 11:75
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Table 6 showed that the frequency of all CAPN10 diplo-
types identified, including the "high-risk haplotype (112/
121) reported for Mexican-Americans and Northern
Europeans, were comparable between patients and con-
trols, even before applying the Bonferroni correction.
Discussion
CAPN10  was the first T2D candidate gene identified
through genome-wide screening and positional cloning
[3,8], and increasing evidence has implicated contribu-
tion of CAPN10  g e n e  v a r i a n t s  i n  t h e  r i s k  o f  T 2 D
[9,10,13]. Specific CAPN10 variant (UCSNP-43) and at-
risk haplotype combination (112/121) defined by
UCSNP-43, -19, and -63 polymorphisms, reportedly con-
fers increased risk of T2D in some but not all populations
[4,9,11,13,15]. Insofar as the Tunisian population (est. 9.6
million) is characterized by a high ethnic diversity,
brought about by the admixture of the native Berbers
(descendants of the Mesolithic Capsian populations) with
principally the invading Arabs in the 7th-8th Century A.D.
[22], we limited our study group to only Tunisians of Arab
descent, so as to minimize the inherent problems associ-
ated with multi-ethnic genetic studies.
We previously investigated the contribution of some
candidate gene variants identified through GWAS
(TCF7L2, HHEX, GCK, ENPP1 and KCNJ11) to T2D in
Tunisian; only TCF7L2  (rs7903146) was significantly
associated with T2D in Tunisians [18], thereby demon-
strating ethnic contribution of the association of specific
gene variants to T2D pathogenesis. In this case-control
study, we examined the contribution of UCSNP-43, -19,
and -63 CAPN10 variants on T2D risk in Tunisians of
Arab origin, which were selected in view of previous
reports linking them with T2D [4,7,14], insulin resistance
[15], obesity [7,9,15], or with altered regulation of
CAPN10 gene expression in Tunisian and other popula-
tions. In the population studied, we could not confirm the
previously described haplotype associated with T2D
(112/121) in Mexican-Americans and in northern-Euro-
pean populations [4,9-11]. UCSNP-19 was shown to
affect the susceptibility to T2D, evidenced by enrichment
of the 2R allele (P = 0.007; OR = 1.15) and homozygous
2R/2R genotype (P = 0.002; OR = 1.61) in T2D patients.
In agreement with previous reports, UCSNP-19, but
UCSNP-43 and UCSNP-63 was associated with height-
ened T2DM risk and increased BMI [6], without ruling
out a role for UCSNP-43 and UCSNP-63 in the develop-
ment of T2DM-related traits (insulin resistance, altered
lipid metabolism), as was suggested [7,15]. Previous stud-
ies implicated UCSNP-19 with altered insulin sensitivity
(HOMA-IR index) in Northern European [17] and Span-
ish [23], but not Scandinavian [15] or Finnish [7] subjects.
Table 4: Linkage Disequilibrium Analysis Between CAPN10 SNPs 1
T2D Patients (n = 917) Controls (n = 748)
Locus 1 Locus 2 D' r2 P D' r2 P
UCSNP-43 UCSNP-19 1.000 0.083 <0.001 1.000 0.076 <0.001
UCSNP-43 UCSNP-63 0.360 0.002 0.190 0.284 0.002 0.314
UCSNP-19 UCSNP-63 0.057 0.001 0.516 0.170 0.004 0.118
1. Analyzed by LDA v.1.0 software.
Table 5: CAPN10 Haplotype Analysis
Haplotype1 Patients Controls PP c 3 OR (95% CI)
1114 0.392 (719) 2 0.345 (516) 2 0.006 0.034 1.22 (1.06 - 1.41)
112 0.072 (132) 0.059 (88) 0.147 0.615 1.24 (0.94 - 1.64)
121 0.368 (675) 0.399 (597) 0.072 0.361 0.88 (0.76 - 1.01)
122 0.080 (147) 0.096 (144) 0.115 0.520 0.82 (0.64 - 1.04)
221 0.078 (143) 0.086 (129) 0.422 0.963 0.90 (0.70 - 1.15)
222 0.010 (18) 0.015 (22) 0.259 0.834 0.66 (0.36 - 1.24)
1. Haplotype frequency determined by the maximum likelihood method.
2. Haplotype frequency (number of haplotypes).
3. Pc = corrected P, calculated as per the Bonferroni method [Pc = 1 - (1 - P)n)], where n = number of comparisons.
4. CAPN10 haplotypes were coded as per the allele at each locus (wild-type = 1, mutant = 2); the first refers to UCSNP-43, the second to UCSNP-
19, and the third to UCSNP-63.Ezzidi et al. BMC Medical Genetics 2010, 11:75
http://www.biomedcentral.com/1471-2350/11/75
Page 6 of 8
Our findings were in agreement with a recent small study
in Southern Tunisia (Djerba Island) involving 162 T2D
patients and 110 control subjects of mixed Arab and non-
Arab (Berber) ancestry, in which UCSNP-19 was associ-
ated with T2D only in the Arab sub-group [24], and in
apparent disagreement with another study in Central
Tunisia (Sfax), in which UCSNP-43, but not UCSNP-19,
was over-represented in T2D patients [25]. While expla-
nations for the discrepancies remain to be seen, they
most likely reside in inadequate statistical power in the
study of Kifagi (226 patients and 206 controls), and in dif-
ferences in subjects' selection (gender distribution, dura-
tion of diabetes, BMI status), which in turn may have
overestimated the association of UCSNP-43 with T2D.
In the Tunisian population studied herein, the most fre-
quent haplotypes were 111 in patients (OR = 1.22) and
121 among controls (OR = 0.88), while haplotype 112 was
detected at low frequencies among controls (0.059) and
patients (0.072). Haplotype 112 is common among Afri-
cans and Asians, but is infrequent in Caucasians, while
haplotype 121 is infrequent in Africans, but common
among Europeans [8,26]. This relatedness of North Afri-
can Tunisians to Europeans in the distribution of the
CAPN10  haplotypes, more so than Africans, may be
explained by the admixture of indigenous African inhab-
itants (Berbers) with Phoenicians (ancestors of present-
day Lebanese), followed by successive migration of Mus-
lims from Arabian Peninsula, Turks (Ottoman rule), and
recently Europeans. The positive association of haplotype
111 with T2D among Tunisians was reminiscent of previ-
ous results linking haplotype 111 with increased T2D risk
in Koreans [27], and with altered insulin sensitivity in
Spanish subjects [23]. The reason for discrepancies in the
association of specific CAPN10  haplotypes, especially
111 haplotype rather than the anticipated 121 haplotype
with T2D remains speculative at this stage. The heteroge-
neity of CAPN10  i n  t h e  m a g n i t u d e  o f  L D  b e t w e e n
CAPN10 variants is likely attributed to ethnic differences,
coupled with sample size differences, and to the failure to
control for possible confounding variables by some of the
studies. Collectively, this may have modulated potential
effects of CAPN10 gene variants on T2D.
Since the first report of Horikawa linking specific
CAPN10  at-risk haplotype combination (112/121)
(defined by UCSNP-43, -19 and -63), with higher risk of
T2D in Mexican-Americans and Europeans [10], a num-
ber of studies performed on diverse populations yielded
often inconsistent association of CAPN10  diplotypes
with T2D risk [9,10]. These haplotype combinations
included 111/121 in Koreans [27], 111/221 in Northern
Europeans [17], 112/221 in Chinese [12], and 121/121 in
pan-Eurpoean populations [9]. We did not identify spe-
cific T2D at-risk CAPN10 haplotype combination,
including the 112/121 diplotype, which was present at
comparable frequencies among healthy controls and T2D
patients.
Table 6: CAPN10 Haplotype Combinations
Diplotype1 Patients Controls PP c   2 OR3(95% CI)
111/111 132 (0.144) 4 88 (0.118) 0.133 0.864 1.26 (0.94 - 1.70)
111/112 45 (0.049) 23 (0.031) 0.079 0.684 1.63 (0.97 - 2.67)
111/121 260 (0.284) 193 (0.258) 0.268 0.987 1.14 (0.91 - 1.41)
111/221 76 (0.083) 57 (0.076) 0.683 1.000 1.10 (0.76 - 1.56)
112/112 4 (0.004) 3 (0.004) 0.947 1.000 0.81 (0.22 - 3.02)
112/121 115 (0.125) 87 (0.116) 0.624 1.000 1.09 (0.81 - 1.46)
112/221 28 (0.031) 32 (0.043) 0.230 0.974 0.70 (0.42 - 1.18)
121/121 132 (0.144) 131 (0.175) 0.095 0.753 0.79 (0.61 - 1.03)
121/221 35 (0.038) 39 (0.052) 0.194 0.951 0.72 (0.45 - 1.15)
221/221 3 (0.003) 5 (0.007) 0.519 1.000 0.49 (0.13 - 1.98)
112/122 10 (0.011) 7 (0.009) 0.946 1.000 1.17 (0.45 - 2.93)
121/122 58 (0.063) 62 (0.083) 0.148 0.894 0.75 (0.52 - 1.08)
122/122 3 (0.003) 8 (0.011) 0.120 0.833 0.30 (0.10 - 1.16)
122/221 16 (0.017) 13 (0.017) 0.859 1.000 1.00 (0.48 - 2.06)
1. CAPN10 haplotypes were coded as per the allele (wild-type = 1, mutant = 2) at each locus; the first refers to UCSNP-43, the second to UCSNP-
19, and the third to UCSNP-63.
2. Pc = corrected P, calculated as per the Bonferroni method [Pc = 1 - (1 - P)n)], where n = number of comparisons.
3. Calculated according to Woolf's method, for specific patient vs. control diplotype carriers.
4. Number (frequency).Ezzidi et al. BMC Medical Genetics 2010, 11:75
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Our findings were in agreement with those reported for
the Scandinavians [15], Koreans [27], and Mexicans [11]
and in meta-analysis conducted in both population-based
and family-based association studies [26] and in prospec-
tive cohort study of multi-ethnic American postmeno-
pausal women [28], in which 112/121 diplotype did not
influence the risk of T2D. It was of interest to note the
association of 121/221 diplotype with increased risk of
T2D among Tunisians (South East Tunisia) [25]. While
the frequency of this diplotype was comparable between
our healthy control group (0.052) and their control
cohort (0.05), marked difference its distribution among
T2D patients was seen between our (0.038) and their
(0.108) T2D patient groups. These discrepancies may be
explained by differences in sample size (226 patients and
206 controls in Kifagi study vs. 917 patients and 748 con-
trols in our study), and thus statistical power, differences
in patient characteristics (BMI, hypertension status, and
T2D duration), and data presentation. Future large-scale
association and functional studies are needed to confirm
or argue against the association of a particular CAPN10
haplotype combination with T2D risk, after controlling
for the ethnic/geographical factor.
Conclusion
In conclusion, we were not able to replicate the associa-
tion between specific CAPN10 alleles identified in earlier
studies and T2D in Tunisians of Arab ancestry. The dif-
ference in the association between CAPN10 variants with
increased risk of T2D between populations (Mexican
Americans, northern-Europeans, Pima Indians) may be
attributed to the presence of multiple susceptibility alleles
at CAPN10 locus, to different linkage disequilibrium pat-
terns of between these variants (and hence haplotypes
and haplotype combinations), racial/ethnic differences in
the distribution of CAPN10 variants, multiple hypothesis
testing, and to inadequate statistical power in a number
of these studies, which has likely overestimated this
genetic association. However, our study has some limita-
tions. It was limited to three SNPs which were selected
based on previous reports, leaving the possibility of the
contribution of other CAPN10 SNPs to T2DM pathogen-
esis among Tunisians to be addressed, together with the
speculation as to if the three SNPs analyzed were suffi-
cient to capture the genetic variability in Tunisian Arabs.
In addition, we did not assign a functional aspect to the
CAPN10  variants and haplotypes included, and it was
limited to a specific ethnic group (North African Tunisian
Arabs). These, coupled with the potential linkage of
CAPN10  polymorphisms investigated with other
CAPN10  or nearby gene polymorphisms, necessitates
large population-based follow-up studies for better
understanding of the contribution that CAPN10 to T2D
risk.
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